Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy

Yulong Fu; Anqi Wang; Jieqi Zhou; Wei Feng; Minhua Shi; Xiao Xu; Hongqing Zhao; Liming Cai; Jian Feng; Xuedong Lv; Xiaodong Zhang; Wenjing Xu; Zhengrong Zhang; Guoer Ma; Jian Wang; Tong Zhou; Dahai Zhao; Haohui Fang; Zeyi Liu; Jian-An Huang

doi:10.3389/fonc.2023.1236311

Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy

Front Oncol. 2023 Jun 27:13:1236311. doi: 10.3389/fonc.2023.1236311. eCollection 2023.

Authors

Yulong Fu^{1

2}, Anqi Wang^{1

2}, Jieqi Zhou^{1

2}, Wei Feng¹, Minhua Shi³, Xiao Xu⁴, Hongqing Zhao⁵, Liming Cai⁶, Jian Feng⁷, Xuedong Lv⁸, Xiaodong Zhang⁹, Wenjing Xu¹⁰, Zhengrong Zhang¹¹, Guoer Ma¹², Jian Wang¹³, Tong Zhou¹⁴, Dahai Zhao¹⁵, Haohui Fang¹⁶, Zeyi Liu^{1

2

17}, Jian-An Huang^{1

2

17}

Affiliations

¹ Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
² Suzhou Key Laboratory for Respiratory Diseases, Suzhou, China.
³ Department of Respiratory Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, China.
⁴ Department of Respiratory Medicine, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
⁵ Department of Respirology, Nanjing Medical University Affiliated Wuxi Second Hospital, Wuxi, China.
⁶ Department of Respiratory Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China.
⁷ Department of Respiratory Medicine, Affiliated Hospital of Nantong University, Nantong, China.
⁸ Department of Respiratory Medicine, The Second Affiliated Hospital of Nantong University, Nantong, China.
⁹ Department of Medical Oncology, Nantong Tumor Hospital, Nantong, China.
¹⁰ Departments of Respiratory Medicine, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou, China.
¹¹ Department of Respiratory Medicine, First People's Hospital of Yangzhou City, Yangzhou, China.
¹² Department of Respiratory Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
¹³ Department of Respiratory Medicine, Zhenjiang First People's Hospital, Zhenjiang, China.
¹⁴ Department of Oncology, Changzhou Cancer Hospital Affiliated to Soochow University, Changzhou, China.
¹⁵ Department of Respiratory and Critical Care Medicine, The Second Hospital of Anhui Medical University, Hefei, China.
¹⁶ Department of Respiratory Medicine, Anhui Chest Hospital, Hefei, China.
¹⁷ Institute of Respiratory Diseases, Soochow University, Suzhou, China.

Abstract

[This corrects the article DOI: 10.3389/fonc.2021.621992.].

Keywords: drug resistance; epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI); gene sequencing; liquid biopsy; non-small cell lung cancer.

Publication types

Published Erratum